Show simple item record

AuthorBenredjem, Besma
AuthorGallion, Jonathan
AuthorPelletier, Dennis
AuthorDallaire, Paul
AuthorCharbonneau, Johanie
AuthorCawkill, Darren
AuthorNagi, Karim
AuthorGosink, Mark
AuthorLukasheva, Viktoryia
AuthorJenkinson, Stephen
AuthorRen, Yong
AuthorSomps, Christopher
AuthorMurat, Brigitte
AuthorVan Der Westhuizen, Emma
AuthorLe Gouill, Christian
AuthorLichtarge, Olivier
AuthorSchmidt, Anne
AuthorBouvier, Michel
AuthorPineyro, Graciela
Available date2019-09-15T05:32:19Z
Publication Date2019-09-01
Publication NameNature Communicationsen_US
Identifierhttp://dx.doi.org/10.1038/s41467-019-11875-6
CitationBenredjem B, Gallion J, Pelletier D, Dallaire P, Charbonneau J, Cawkill D, Nagi K, Gosink M, Lukasheva V, Jenkinson S, Ren Y, Somps C, Murat B, Van Der Westhuizen E, Le Gouill C, Lichtarge O, Schmidt A, Bouvier M, Pineyro G. Exploring use of unsupervised clustering to associate signaling profiles of GPCR ligands to clinical response. Nat Commun. 2019 Sep 9;10(1):4075. doi: 10.1038/s41467-019-11875-6.
URIhttp://hdl.handle.net/10576/11828
AbstractSignaling diversity of G protein-coupled (GPCR) ligands provides novel opportunities to develop more effective, better-tolerated therapeutics. Taking advantage of these opportunities requires identifying which effectors should be specifically activated or avoided so as to promote desired clinical responses and avoid side effects. However, identifying signaling profiles that support desired clinical outcomes remains challenging. This study describes signaling diversity of mu opioid receptor (MOR) ligands in terms of logistic and operational parameters for ten different in vitro readouts. It then uses unsupervised clustering of curve parameters to: classify MOR ligands according to similarities in type and magnitude of response, associate resulting ligand categories with frequency of undesired events reported to the pharmacovigilance program of the Food and Drug Administration and associate signals to side effects. The ability of the classification method to associate specific in vitro signaling profiles to clinically relevant responses was corroborated using β2-adrenergic receptor ligands.
SponsorThis research was supported by a research contract from Pfizer Inc. and grants from the Natural Sciences and Engineering Research Council of Canada (Grant 311997 to G.P.) and the Canadian Institutes of Health Research MOP 324876 (to G.P.), MOP 102630 (to M.B. and O.L.) and Foundation grant (FDN-148431) to MB. MB holds a Canada Research Chair in Signal Transduction and Molecular Pharmacology. Dr Lichtarge’s research was supported by National Institutes of Health (NIH 2R01 GM066099; NIH 5R01 GM079656). B.B. was supported by a studentship from Fonds de Recherche en Santé du Québec. P.D. was supported by a MITACS fellowship.
Languageen
PublisherSpringer Nature
SubjectClinical responses
SubjectGPCRs
SubjectBias signaling
SubjectSignaling profiles
SubjectClustering
TitleExploring use of unsupervised clustering to associate signaling profiles of GPCR ligands to clinical response.
TypeArticle
Issue Number1
Volume Number10
ESSN2041-1723


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record